ASCO in retrospect - Sharing Best Practice

Sonia Trial

ACSO 2023

Sonia trial: How does the new data change clinical…

D. Lüftner, V. Müller, G. Curigliano, A. Schneeweiss, H. Rugo, W. Janni

ASCO 2023

ADC revolution: How can the new results be integrated…

D. Lüftner, V. Müller, G. Curigliano, A. Schneeweiss, H. Hugo, W. Janni

ASCO 2023

CDK4/6i in EBC: Have abema and ribo arrived in the…

N. Harbeck, S. Tolaney, G. Curigliano, P. Fasching, K. Gelmon, V. Diéras, G.Morgan, E- Senkus-Konefka

ASCO 2023

Discussions and controversies on social-media: what is…

N. Harbeck, S. Tolaney, G. Curigliano, P. Fasching, K. Gelmon, V. Diéras, G. Morgan, E. Snus-Konefka, M. Untch

Early breast Cancer - Discussions ENG

NATALEE

ASCO 2023

Expanding CDK4/6i therapy in EBC: How to select…

W. Janni, G. Curigliano

SOFT

ASCO 2023

PART2: Trying to understand optimal therapy for…

N. Harbeck, W. Janni, H. Rugo, J. Cortes, A. Gennari, G. Curigliano

PHERGain

ASCO 2023

PART1: How to de-escalate chemotherapy? What is the…

N. Harbeck, W. Janni, H. Rugo, J. Cortes, A. Gennari, G. Curigliano

NATALEE, MonarchE, PENELOPE-B

ASCO 2023

CDK4/6 inhibitors in EBC: Amazing data, but longer…

N. Harbeck, W. Janni, H. Rugo, J. Cortes, A. Gennari

Perspectives of EBC treatment

NATALEE

ASCO 2023

New data on Ribocilib in adjuvant setting EBC: What…

D. Lüftner, H. Rugo, E. Senkus, G. Curigliano, C. Criscitello, E. Ciruelos, A. Gennari, P. Fasching, K. Gelmon

PHERGain

ASCO 2023

Chemotherapy de-escalation in HER2+ patients:…

D. Lüftner, H. Rugo, E. Senkus, G. Curigliano, C. Criscitiello, A. Gennari, P. Fasching, K. Gelmon

Meta Analyses

ASCO 2023

Data from Meta-Analyses of almost 15k Patients: Who…

D. Lüftner, H. Rugo, E. Senkus, G. Curigliano, C. Criscitello, E. Ciruelos, A. Gennari, P. Fasching, K. Gelmon

Breast cancer early - 100 seconds ENG

PHERGain

ASCO 2023

PHERGain opens the possibility to avoid chemotherapy in…

Javier Cortés, MD

TORCHLIGHT

ASCO 2023

Another proof of efficacy of immunotherapy in advanced…

Elzbieta Senkus, MD, PhD

PHERGain

ASCO 2023

1/3 of patients with HER2+ in future without…

Wolfang Janni, MD

ASCO 2023

Ovarian function - Ovarian suppression not necessary in…

Wolfang Janni, MD

PHERGain

ASCO 2023

Can we preserve our patients form chemotherapy?

Shani Paluch-Shimon, MD

NATALEE, MonarchE, PENELOPE-B

ASCO 2023

My EBC highlights from ASCO23

Giuseppe Curigliano, MD

NATALEE

ASCO 2023

More CDK4/6 options for EBC patients

Diana Lüftner, MD; Michael Untch, MD

ASCO 2023

TILs subtypes are associated with clinical features and…

Andreas Schneeweiss, MD

PHERGain

ASCO 2023

A challenge for clinical management

Diana Lüftner, MD

PENELOPE-B

ASCO 2023

Analyses of ctDNA in PENELOPE-B: Test methods are…

Peter Fasching, MD

NATALEE, MonarchE, PENELOPE-B

ASCO 2023

Discussions on CDK4/6 inhibitors in EBC

Nadia Harbeck, MD

PENELOPE-B

ASCO 2023

Tumor-informed ctDNA likely prognostic for relapse in…

Andreas Schneeweiss, MD

PENELOPE-B

ASCO 2023

From PENELOPE-B to SURVIVE

Wolfang Janni, MD

PHERgain

ASCO 2023

Response adapted, chemotherapy-free option in HER2+ EBC

Andreas Schneeweiss, MD

NATALEE

ASCO 2023

Ribociclib improves iDFS

Sara Tolaney, MD

ASCO 2023

TILs are prognostic but not predictive in HER2+ EBC

Andreas Schneeweiss, MD

NATALEE

ASCO 2023

Practice changing or not quite yet?

Elzbieta Senkus-Konefka, MD

GeparNuevo

ASCO 2023

White blood cells with increasing prognostic relevance?…

Peter Fasching, MD

NATALEE

ASCO 2023

Ribociclib has arrived in the adjuvant setting

Peter Fasching, MD

NATALEE

ASCO 2023

First data with adjuvant ribociclib

Michael Untch, MD

PALMIRA

ASCO 2023

Palbociclib after Palbociclib might not be the best…

Javier Cortes, MD

NATALEE, MonarchE

ASCO 2023

Early follow-up shows clear benefit

Shani Paluch-Shimon, MD

ShortHER

ASCO 2023

10 years update on ShortHER

Alessandra Gennari, MD; Valentina Guaneri, MD

ENG

Meta-Analyses, SOFT

ASCO 2023

Young patients benefit from ovarian suppression

Karen Gelmon, MD

ASCO 2023

SOC of ovarian ablation confirmed in meta-analysis.

Andreas Schneeweiss, MD

ASCO 2023

TILs in HER2+ disease - prognostic, but not enough to…

Elzbieta Senkus, MD, PhD

NeoPACT

ASCO 2023

Chemo-immunotherapeutic signals especially in HER2low…

Andreas Schneeweiss, MD

PHERGain

ASCO 2023

De-escalation of CT for early BC

Sara Tolaney, MD

RUBY

ASCO 2023

Checkpoint inhibition in endometrial cancer: new…

Diana Lüftner, MD

Breast Cancer early 100 seconds - multi language

NeoPACT

ASCO 2023

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

Andreas Schneeweiss, MD

TORCHLIGHT

ASCO 2023

Kolejny dowód na skuteczność immunoterapii w…

Elzbieta Senkus-Konefka, MD

ASCO 2023

TILs w rakach HER2+ - znaczenie rokownicze, ale nie…

Elzbieta Senkus-Konefka, MD

NATALEE

ASCO 2023

Czy wystarczy, aby zmienić standardy?

Elzbieta Senkus-Konefka, MD

ASCO 2023

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

Andreas Schneeweiss, MD

NATALEE

ASCO 2023

NATALEE nicht überraschend aber überzeugend positiv

Wolfang Janni, MD

NATALEE

ASCO 2023

Eine Herausforderung für viele Patienten, wenig…

Diana Lüftner, MD

PALMIRA

ASCO 2023

Palbociclib después de Palbociclib podría no ser la…

Javier Cortes, MD

PHERGain

ASCO 2023

PHERGain abre la posibilidad de evitar la quimioterapia…

Javier Cortes, MD

ASCO 2023

TILs Subtypen sind assoziiert mit klinischen Merkmalen…

Andreas Schneeweiss, MD

PHERgain

ASCO 2023

1/3 der Patientinnen mit HER2+ zukünftig ohne…

Wolfang Janni, MD

NATALEE, MonarchE, PENELOPE-B

ASCO 2023

I miei punti salienti di ASCO23

Giuseppe Curigliano, MD

NATALEE

ASCO 2023

Primele date cu ribociclib adjuvant

Michael Untch, MD

PENELOPE-B

ASCO 2023

Tumor-informed ctDNA wahrscheinlich prognostisch für…

Andreas Schneeweiss, MD

PHERGain

ASCO 2023

Eine Herausforderung für das klinische Management

Diana Lüftner, MD

ASCO 2023

Ovar Funktion - Ovarielle Supression verzichtbar bei…

Wolfang Janni, MD

PHERGAIN

ASCO 2023

Response adaptierte, Chemotherapie-freie Option beim…

Andreas Schneeweiss, MD

ASCO 2023

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Andreas Schneeweiss, MD

PENELOPE-B

ASCO 2023

Von PENELOPE-B zur SURVIVE

Wolfang Janni, MD

Breast cancer metastatic - 100 seconds ENG

TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04

ASCO 2023

Updates on ADCs in metastatic breast cancer

Barbara Pistilli, MD

PADA-1

ASCO 2023

The start of precision medicine in HR+ breast cancer

Karen Gelmon, MD

PreCycle

ASCO 2023

E-Health Applications in Oral Cancer Therapy

Nadia Harbeck, MD

PALMIRA, MAINTAIN (ASCO22), PACE (SABCS22)

ASCO 2023

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

Carmen Criscitiello, MD

SONIA

ASCO 2023

What is the optimal therapie sequence for HR+ MBC…

Karen Gelmon, MD

18F-FES

ASCO 2023

Molecular imaging for endocrine responsivness

Alessandra Gennari, MD; Valentina Guaneri, MD

TROPiCS-02

ASCO 2023

Continued OS benefit for Sacituzumab Govitecan

Sara Tolaney, MD

Breast cancer metastatic 100 seconds - multi language

TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04

ASCO 2023

Aggiornamenti sugli ADC nel carcinoma mammario…

Barbara Pistilli, MD

TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04

ASCO 2023

Mises à jour sur les ADC dans le cancer du sein…

Barbara Pistilli, MD

PALMIRA, MAINTAIN (ASCO22), PACE (SABCS22)

ASCO 2023

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo…

Carmen Criscitiello, MD

MBC - Discussions

SONIA, PALMIRA, PADA-1

ASCO 2023

CDK4/6 Sequencing? ESR-1 not ready for prime time?…

K. Gelmon, V. Müller, E. M. Ciruelos, E. Senkus-Konefka, N. Harbeck, B. Pistilli, H. Rugo

TROPICS-02, HER3 DxD

ASCO 2023

Update ADC efficacy

K. Gelmon, V. Müller, E. M. Ciruelos, E. Senkus-Konefka, N. Harbeck, B. Pistilli, H. Rugo

SONIA, PALMIRA, PADA-1

ASCO 2023

CDK4/6i in first line and beyond & Biomarkers

K. Gelmon, V. Müller, E. M. Ciruelos, E. Senkus-Konefka, N. Harbeck, B. Pistilli, H. Rugo

CANKADO

ASCO 2023

The value of eHealth

K. Gelmon, V. Müller, E. M. Ciruelos, E. Senkus-Konefka, N. Harbeck, B. Pistilli, H. Rugo

Prostate cancer - 100 seconds eng

TRANSPORT

ASCO 2023

Part2: Important update on testosterone-recovery

Simon Chowdhury, PhD

ASCO 2023

Metastasis-directed for prostate cancer

Simon Chowdhury, PhD

PRL02

ASCO 2023

PRL-02: Intramuscular arbiraterone

Neal Shore, MD

NRG/RTOG

ASCO 2023

AI for prediction in local prostate carcinoma

Philipp Ivanyi, MD

PEACE-1

ASCO 2023

PEACE 1 - results and controversies

Gil Morgan, MD

LuPARP

ASCO 2023

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Anders Bjartell, MD, PhD

TRANSPORT

ASCO 2023

Part 1: Important update on testosterone-recovery

Simon Chowdhury, PhD

Educational Session PCA

ASCO 2023

Intensified or de-intensified therapy in mHSPC

Anders Bjartell, MD, PhD

TALAPRO-2

ASCO 2023

PAPR-inhibitors: Patient-selection matters!

Ignacio Duran, MD

REASSURE

ASCO 2023

Reassuring real-world data!

Simon Chowdhury, PhD

ICECAP

ASCO 2023

PSA nadir 6 month after Radiotherapy is strong…

Anders Bjartell, MD, PhD

DEAR

ASCO 2023

DEAR trial: real-world comparator analyses of ARIs

Neal Shore, MD

TALAPRO-2

ASCO 2023

Confirming results for PARPi in mCRPC

Eleni Efstathiou, MD

ASCO 2023

Over-staging of bone scan compared with PSMA PET/CT

Anders Bjartell, MD, PhD

ARASEC

ASCO 2023

ARASEC: ADT + Daralutamide for mHSPC

Neal Shore, MD

TALAPRO-2

ASCO 2023

TALAPRO-2: Results and controversies

Gil Morgan, MD

Prostate Cancer 100 seconds - multi language

ESP

TALAPRO-2

ASCO 2023

PARP-inhibitors: La selección de pacientes es…

Ignacio Duran, MD

SWE

ASCO 2023

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

Anders Bjartell, MD

SWE

Educational Session PCa

ASCO 2023

Intensifierad eller de-intensifierad behandling vid…

Anders Bjartell, MD

SWE

ICECAP

ASCO 2023

PSA nadir 6 månader efter radioterapi är en prognostisk…

Anders Bjartell, MD

LuPARP

ASCO 2023

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Anders Bjartell, MD

GRE

TALAPRO-2

ASCO 2023

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Eleni Efstathiou, MD

Prostate cancer - Discussions ENG

ASCO 2023

What is your preferred sequence in 1st line treatment…

E. Efstathiou, L.-M. Krabbe, M.-O. Grimm, A. Bjartell, S. Chowdhury

TALAPRO-2

ASCO 2023

PARPi in PCa: more genetic testing is required as PRO…

E. Efstathiou, A. S. Merseburger, L.-M. Krabbe, M.-O. Grimm, A. Bartjell, S. Chowdhury

PEACE-1

ASCO 2023

Triple therapy in mCSPC - which is the ideal partner…

E. Efstathiou, A. S. Merseburger, L.-M. Krabbe, M.-O. Grimm, A. Bjartell, S. Chowdhury

Bladder cancer - 100 seconds ENG

VESPER, THOR, SWOG S1011, NORSE

ASCO 2023

Best of Bladder: ddMVC increases DFS! Standard…

Petros Grivas, MD, PhD

THOR

ASCO 2023

The beginning of a new era in urothelial cancer?!

Tom Powles, MD

JAVELIN BLADDER 100

ASCO 2023

Q-TWiST in the therapy of aUC

Oliver Grimm, MD

EV-103

ASCO 2023

First line in cisplatin-ineligible advance urothelial…

Ignacio Duran

THOR

ASCO 2023

New SoC option for metastatic bladder cancer

Yohann Loriot, MD

SWOG S1011

ASCO 2023

Extent of lymphadenectomy in cystectomy

Laura-Maria Krabbe, MD

THOR

ASCO 2023

FGFR inhibition

PD Dr. med. Philipp Ivanyi

EV-103

ASCO 2023

Enfortumab vedotin + pembrolizumab 1stL in…

Oliver Grimm, MD

VESPER

ASCO 2023

New standard for MIBC

PD Dr. med. Philipp Ivanyi

THOR

ASCO 2023

Targeted therapies in advanced urothelial cancer: The…

Ignacio Duran, MD

Bladder cancer 100 second - multi language

VESPER, THOR, SWOG S1011, NORSE

ASCO 2023

Best of Bladder: ddMVC increases DFS! Standard…

Petros Grivas, MD, PhD

THOR

ASCO 2023

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El…

Ignacio Duran, MD

THOR

ASCO 2023

Nouvelles options de soins standard pour le cancer de…

Yohann Loriot, MD

EV-103

ASCO 2023

Primera línea en cáncer urotelial avanzado no elegible…

Ignacio Duran, MD

Bladder cancer - Discussions

Study EV-103, JAVELIN Bladder 100

ASCO 2023

Update EV/Pembro, Avelumab Maintenance

T. Powles, P. Grivas, L.-M. Krabbe, J. Bellmunt, Y. Loriot, M.-O. Grimm

VESPER

ASCO 2023

The efficacy of neo-adjuvant therapy (ddMVAC,…

T. Powles, P. Grivas, L.-M. Krabbe, J. Bellmunt, Y. Loriot, M.-O. Grimm

THOR, NORSE, PROOF 302

ASCO 2023

The efficacy of FGFR targeting

T. Powles, P. Grivas, L.-M. Krabbe, J. Bellmunt, Y. Loriot, M.-O. Grimm

Kidney cancer - Discussions

KEYNOTE-B61

ASCO 2023

Non ccRCC: how should we treat patients today?

H. Hammers, T. Powles, P. Ivanyi

CBM588

ASCO 2023

The impact of microbiome and supplements on therapy…

L.-M. Krabbe, P. Ivanyi, H. Hammers, S.K. Pal

Keynote-426 CLEAR

ASCO 2023

Long term follow up in advanced renal cell cancer: Is…

L.-M. Krabbe, P.Ivanyi, H. Hammers, S. K. Pal, T. Powles, M.-O. Grimm

CONTACT-03

ASCO 2023

Primary endpoint not reached: what do we learn from…

T. Powles, H. Hammers, P. Ivanyi, L.-M. Krabbe

Kidney cancer - 100 seconds eng

KEYNOTE-426, CLEAR

ASCO 2023

Update and take home message of 1st Line mRCC

PD Dr. med. Philipp Ivanyi

Keynote-426, CLEAR

ASCO 2023

Long-term follow-up for IO/TKI in mRCC

Laura-Maria Krabbe, MD

CONTACT-03

ASCO 2023

IO rechallenge in mRCC

Laura-Maria Krabbe, MD

KEYNOTE-B61

ASCO 2023

Lenvatinib + pembrolizumab in non-clear cell renal cell…

Oliver Grimm, MD

CONTACT-03

ASCO 2023

New standard for 2nd line RCC?

Philipp Ivanyi, MD

KEYNOTE-B61

ASCO 2023

New data non ccRCC

PD Dr. med. Philipp Ivanyi

CheckMate 314

ASCO 2023

News from the adjuvant

Philipp Ivanyi, MD

Keynote-426, CLEAR

ASCO 2023

1st Line therapy RCC: which combination to choose?

Tom Powles, MD

NSCLC early stages - Discussion

ADAURA

ASCO 2023

ADAURA: Osimertinib improves survival in the treatment…

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah

CheckMate 816, IMpower010, KEYNOTE-671, NEOTORCH

ASCO 2023

The value of perioperative chemo-IO in rNSCLC and the…

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah

NSCLC early stages - 100 seconds ENG

CheckMate 9LA

ASCO 2023

CheckMate 9LA: 4‑year clinical update

Martin Reck, MD

ADAURA

ASCO 2023

ADAURA - results and controversies

Gil Morgan, MD

CheckMate 816, ADAURA

ASCO 2023

Adjuvant and neoadjuvant strategies in resectable NSCLC

Nicolas Girard, MD

KEYNOTE-671

ASCO 2023

Perioperative treatment

Hossein Borghaei

ADAURA, KEYNOTE-671

ASCO 2023

More options in the perioperative setting

Noemi Reguart, MD

KEYNOTE-671

ASCO 2023

Another neoadjuvant chemo/IO option

Riyaz Shah, MD

KEYNOTE-671, NEOTORCH

ASCO 2023

Induction options in the perioperative setting

Michael Thomas, MD

KEYNOTE-671

ASCO 2023

Which should we prefer: neoadjuvant, adjuvant or…

Denis Moro-Sibilot, MD

KEYNOTE-671, CheckMate-816

ASCO 2023

Confirmation of neoadjuvant immunotherapy

Frank Griesinger, MD

KEYNOTE-671

ASCO 2023

Role of periopertative IO confirmed

Sacha Rothschild, MD

ADAURA

ASCO 2023

A new standard of care for operated patients with…

Denis Moro-Sibilot, MD

ADAURA

ASCO 2023

ADAURA - Discussion closed?

Lizza Hendriks, MD, PhD

ADAURA

ASCO 2023

A new standard of care

Riyaz Shah, MD

EAST ENERGY

ASCO 2023

A chemo-free preop. IO strategy?

Riyaz Shah, MD

ADAURA

ASCO 2023

EGFR testing necessary in the adjuvant setting

Diana Lüftner, MD

KEYNOTE-671

ASCO 2023

Added benefit of perioperative chemo/IO in stage 2-3b…

Lizza Hendriks, MD, PhD

IMpower010

ASCO 2023

Adjuvant IO in KRASm patients

Martin Reck, MD

ADAURA

ASCO 2023

OS benefit from EGFR receptor TKI

Frank Griesinger, MD

ADAURA

ASCO 2023

An imperfect analysis, but perfect results

Stephen Liu, MD

NSCLC early stages 100 seconds - multi language

ADAURA

ASCO 2023

ADAURA- discussie gesloten?

Lizza Hendriks, MD, PhD

KEYNOTE-671

ASCO 2023

Toegevoegde waarde van periperatief chemo-immuno bij…

Lizza Hendriks, MD, PhD

ADAURA

ASCO 2023

Un nouveau standard therapeutique pour les patients…

Denis Moro-Sibilot, MD

KEYNOTE-671

ASCO 2023

Que devrions-nous préférer: traitement néoadjuvant,…

Denis Moro-Sibilot, MD

CheckMate 816, ADAURA

ASCO 2023

Stratégies adjuvantes et néoadjuvantes dans le CBNPC…

Nicolas Girard, MD

ADAURA, KEYNOTE-671

ASCO 2023

Más opciones en el entorno perioperatorio

Noemi Reguart, MD

KEYNOTE-671

ASCO 2023

Rolle der periopertativen IO bestätigt

Sacha Rotschild, MD

NSCLC metastatic - Discussions

LUNAR

ASCO 2023

TTF-treatment requires further studies

M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah, L. Hendriks, S. Liu, H. Borghaei, D. Moro-Sibilot

CodeBreaK 200

ASCO 2023

Sotorasib: clear clinical benefit, but short follow-up…

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah, L. Hendriks, S. Liu, D. Moro-Sibilot

ASCO 2023

Zorifertinib: an option when osimertinib is not…

M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah, L. Hendriks, S. Liu, H. Borghaei, D. Moro-Sibilot

TROPION-Lung02

ASCO 2023

Does ADC + chemo + IO replace the existing concepts?

M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah, L. Hendriks, S. Liu, H. Borghaei, D. Moro-Sibilot

SCARLET, KontRASt-01

ASCO 2023

Update on KRASG12Cm treatment options - how to proceed?

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah, L. Hendriks, S. Liu, D. Moro-Sibilot

KEYNOTE-789

ASCO 2023

Pembro + chemo in pts with TKI-resistant EGFRm /…

M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah, L. Hendriks, S. Liu, H. Borghaei, D. Moro-Sibilot

NSCLC metastatic - 100 seconds eng

TROPION-Lung02

ASCO 2023

TROP2-ADC shows high response rates in 1L-combination…

Stephen Liu, MD

ASCO 2023

Stopping treatment is ok

Riyaz Shah, MD

KEYNOTE-789

ASCO 2023

IO in EGRF positive patients post TKI

Hossein Borghaei

LUNAR

ASCO 2023

LUNAR: TTF medical device shows OS-benefit, but more…

Stephen Liu, MD

TROPION-Lung02

ASCO 2023

ADC + ICI ± Pt-CT in patients with aNSCLC

Nicolas Girard, MD

CORRELATE

ASCO 2023

CORRELATE - a real world analysis

Stephen Liu

SCLC - Discussions

ASCO 2023

Hyperfractionation - an interestingh concept, but not…

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah

ASCO 2023

New data from another BiTE

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah

SCLC - 100 seconds ENG

SWOG 1929

ASCO 2023

Can we incoporate biomarkers in SCLC treatment?

Lizza Hendriks, MD, PhD

ASCO 2023

More BiTEs, more possibilities

Noemi Reguart, MD

SWOG 1929

ASCO 2023

A positive trial with no impact

Stephen Liu

SWOG 1929

ASCO 2023

Treatment strategies in SCLC

Nicolas Girard, MD

ASCO 2023

Hyperfractionated radiotherapy for SCLC

Frank Griesinger, MD

SCLC 100 seconds - multi language

SWOG 1929

ASCO 2023

Stratégies de traitement dans le SCLC

Nicolas Girard

ASCO 2023

Más BiTEs, más posibilidades

Noemi Reguart, MD

SWOG 1929

ASCO 2023

Kunnen we biomarkers gebruiken om behandeling te…

Lizza Hendriks, MD, PhD

Varia 100 seconds - ENG

IND277

ASCO 2023

No practice-changing data in mesothelioma, other…

F. Griesinger, M. Reck, M. Thomas, N. Reguart, N. Girard, R. Shah

PROspect

ASCO 2023

ONCOalert (inclusive patient advocates) consensus on…

Gil Morgan, MD

IND227

ASCO 2023

Immune checkpoint inhibitors in malignant mesothelioma

Sacha Rotschild, MD

Varia 100 seconds - Multi language

IND227

ASCO 2023

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom

Sacha Rotschild, MD